Liise-anne Pirofski

Last updated
Liise-anne Pirofski
Born
Geneva, Switzerland
Alma mater University of California, Berkeley (BA)
Albert Einstein College of Medicine (MD)
Known forInfectious diseases
Scientific career
InstitutionsAlbert Einstein College of Medicine

Liise-anne Pirofski is a Professor of Medicine, Microbiology and Immunology at Albert Einstein College of Medicine and Montefiore Medical Center. [1] She is a Member of the Association of American Physicians, and a Fellow of the American Association for the Advancement of Science, American Academy of Microbiology, American College of Physicians and the Infectious Diseases Society of America.

Contents

Early life and education

Pirofski grew up in Northern California, close to U.S. Route 101. [2] When she was a child she wanted to become an announcer for the San Francisco Giants. [2] At the age of sixteen she attended University of California, Berkeley. [2] [3] She studied history of art and psychology. [3] She was particularly fascinated by the different representations of the Dance of Death , an artistic genre that visualises the personification of death from all walks of life. This made Pirofski interested in the impact of disease on society. [3] During the end of her college degree she decided to pursue a career in medicine. [3] She received her Doctorate of Medicine (MD) at the Albert Einstein College of Medicine in 1982 and trained in internal medicine at Bellevue Hospital. [3] At the time the HIV/AIDS epidemic was unfolding in the United States and many patients Pirofski and her colleagues at Bellevue cared for were suffering and dying from the disease. Her experience caring for patients with HIV/AIDS, a new disease at that time, led her to pursue a career path as a physician-scientist specializing in infectious diseases. Her clinical experiences led her to see the need for more science to understand why even when powerful and antibiotics were available, like for the pneumococcus or cryptococcus, they could not prevent the recurrence of pneumococcal or mortality from cryptococcal disease [3] Her experiences during her medical training inspired Pirofski to train as a scientist focused on understanding how vaccines work and immunotherapy. [3] She trained in the laboratory of Matthew Scharff, working on the structure and function of antibodies to encapsulated pathogens. [2] She joined the faculty at the Albert Einstein College of Medicine in 1988. [4]

Research and career

Pirofski is interested in innate and vaccine-induced immunity to encapsulated microbes. [5] She studies the immune response to the mycosis Cryptococcosis and the bacterium Streptococcus pneumoniae . [4] [6] She has explored antibody-based therapies for the treatment of infectious diseases. [7] In the early 2000s, in collaboration with Arturo Casadevall, Pirofski developed the ‘Damage-Response Framework’ of microbial pathogenesis; which is a theory focused on the outcome of host-microbe interaction that considers the role of both hosts and pathogens in the outcome of infectious diseases and microbial pathogenesis. [8] Pirofski was appointed chief of the division of infectious diseases at Albert Einstein College of Medicine and Montefiore Medical Center in 2006. [9]

During the COVID-19 pandemic Pirofski looked to deploy convalescent plasma, a therapy with a century long history of use in epidemics, as a treatment for COVID-19. [10] She, along with colleagues in New York City and Connecticut, is leading a clinical trial of convalescent plasma, a form of antibody-based therapy for the disease. [10] The treatment involves the administration of convalescent plasma, the liquid portion of blood containing antibodies to SARS-CoV-2, which is obtained from people who have recently recovered from COVID-19. [10] [11] [12] This type of treatment is being studied for its efficacy in patients who are exposed to SARS-CoV-2, as well as those suffering from COVID-19. [10] [13] Convalescent plasma therapy is a form of passive immunization that provides patients with antibodies to fight the disease. In the absence of a vaccine, passive immunization is a powerful way to provide antibodies and boost the immune system of people with SARS-CoV-2 [14] and may remain particularly important for immunocompromised people who may not be able to mount a strong vaccine response. The treatment was approved by the Food and Drug Administration on March 24, 2020. [15] and as of July 2020 numerous randomized controlled clinical trials of its efficacy in hospitalized patients and outpatients are ongoing. Pirofski has found the way in which recovered patients came forth to donate their plasma to treat others heartwarming and a celebration of their spirit and courage in wanting to help others and contribute to the advancement of evidence based science. [16]

Pirofski has been chief of the Division of Infectious Diseases and the Jacques and Selma Mitrani Chair in Biomedical Research at Albert Einstein College of Medicine and Montefiore Medical Center since 2006. [17] In an article describing her career as a physician scientist, she wrote “The greatest treasure my career has brought is the opportunity to support and encourage others in their effort to make inroads in the fields of infectious diseases, immunity, and microbial pathogenesis. Although my own accomplishments and the advances to which I have contributed are very satisfying, what makes my days worthwhile is the thought that my support and encouragement might help others make discoveries that may alleviate suffering and improve human health.” [18]

Awards and honours

Dr. Pirofski is a Fellow of the Infectious Diseases Society of America [25] and the American College of Physicians. [2]

Selected publications

Related Research Articles

Antiserum is a blood serum containing monoclonal or polyclonal antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

Serology is the scientific study of serum and other body fluids. In practice, the term usually refers to the diagnostic identification of antibodies in the serum. Such antibodies are typically formed in response to an infection, against other foreign proteins, or to one's own proteins. In either case, the procedure is simple.

<span class="mw-page-title-main">Stanley Falkow</span> American microbiologist

Stanley "Stan" Falkow was an American microbiologist and a professor of microbiology at Georgetown University, University of Washington, and Stanford University School of Medicine. Falkow is known as the father of the field of molecular microbial pathogenesis. He formulated molecular Koch's postulates, which have guided the study of the microbial determinants of infectious diseases since the late 1980s. Falkow spent over 50 years uncovering molecular mechanisms of how bacteria cause disease and how to disarm them. Falkow also was one of the first scientists to investigate antimicrobial resistance, and presented his research extensively to scientific, government, and lay audiences explaining the spread of resistance from one organism to another, now known as horizontal gene transfer, and the implications of this phenomenon on our ability to combat infections in the future.

<span class="mw-page-title-main">Montefiore Medical Center</span> Hospital in New York, United States

Montefiore Medical Center is a premier academic medical center and the primary teaching hospital of the Albert Einstein College of Medicine in the Bronx, New York City. Its main campus, the Henry and Lucy Moses Division, is located in the Norwood section of the northern Bronx. It is named for Moses Montefiore and is one of the 50 largest employers in New York. In 2020, Montefiore was ranked No. 6 New York City metropolitan area hospitals by U.S. News & World Report. Adjacent to the main hospital is the Children's Hospital at Montefiore, which serves infants, children, teens, and young adults aged 0–21.

Passive immunity is the transfer of active humoral immunity of ready-made antibodies. Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin are transferred to non-immune persons through blood products that contain antibodies, such as in immunoglobulin therapy or antiserum therapy. Passive immunization is used when there is a high risk of infection and insufficient time for the body to develop its own immune response, or to reduce the symptoms of ongoing or immunosuppressive diseases. Passive immunization can be provided when people cannot synthesize antibodies, and when they have been exposed to a disease that they do not have immunity against.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, intracellular bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy.

In biology, a pathogen, in the oldest and broadest sense, is any organism or agent that can produce disease. A pathogen may also be referred to as an infectious agent, or simply a germ.

<span class="mw-page-title-main">Edward Thomas Ryan</span>

Edward Thomas Ryan is an American microbiologist, immunologist, and physician at Harvard University and Massachusetts General Hospital. Ryan served as president of the American Society of Tropical Medicine and Hygiene from 2009 to 2010. Ryan is Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, Professor of Medicine at Harvard Medical School, and Director of Global Infectious Diseases at the Massachusetts General Hospital. Ryan's research and clinical focus has been on infectious diseases associated with residing in, immigrating from, or traveling through resource-limited areas. Ryan is a Fellow of the American Society of Microbiology, the American Society of Tropical Medicine and Hygiene, the American College of Physicians, and the Infectious Diseases Society of America.

<span class="mw-page-title-main">Arturo Casadevall</span> Cuban-American scientist

Arturo Casadevall is a Bloomberg Distinguished Professor of Molecular Microbiology & Immunology and Infectious Diseases at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, and the Alfred and Jill Sommer Professor and Chair of the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. He is an internationally recognized expert in infectious disease research, with a focus on fungal and bacterial pathogenesis and basic immunology of antibody structure-function. He was elected a member of the National Academy of Sciences in 2022.

Professor Ravindra "Ravi" Kumar Gupta is a professor of clinical microbiology at the Cambridge Institute of Therapeutic Immunology and Infectious Disease at the University of Cambridge. He is also a member of the faculty of the Africa Health Research Institute in Durban, South Africa.

Viviana Simon is a Professor of Microbiology at the Icahn School of Medicine at Mount Sinai (ISMMS). She is a member of the ISMMS Global Health and Emerging Pathogens Institute. Her research considers viral-host interactions and the mode of action of retroviral restriction factors. During the COVID-19 pandemic, Simon developed an antibody test that can determine immunity to Coronavirus disease 2019.

<span class="mw-page-title-main">Convalescent plasma</span> Blood plasma from disease survivor

Convalescent plasma is the blood plasma collected from a survivor of an infectious disease. This plasma contains antibodies specific to a pathogen and can be used therapeutically by providing passive immunity when transfusing it to a newly infected patient with the same condition. Convalescent plasma can be transfused as it has been collected or become the source material for the hyperimmune serum which consists largely of IgG but also includes IgA and IgM. or as source material for anti-pathogen monoclonal antibodies, Collection is typically achieved by apheresis, but in low-to-middle income countries, the treatment can be administered as convalescent whole blood.

Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

<span class="mw-page-title-main">Colleen Kraft</span> American medical researcher

Colleen S. Kraft is an infectious disease physician, associate professor in the Department of Pathology and Laboratory Medicine, and the director of the Clinical Virology Research Laboratory at Emory University School of Medicine. In 2014, she led Emory University Hospital's effort to treat and care for Ebola virus disease patients and is currently working to address the COVID-19 pandemic in Georgia. She currently serves on Georgia's COVID-19 task force.

JoAnne L. Flynn is an American microbiologist and immunologist. She is a distinguished professor at the University of Pittsburgh School of Medicine where she researches mycobacterium tuberculosis pathogenesis and immunology. She was president of the American Association of Immunologists.

Although several medications have been approved in different countries as of April 2022, not all countries have these medications. Patients with mild to moderate symptoms who are in the risk groups can take nirmatrelvir/ritonavir or remdesivir, either of which reduces the risk of serious illness or hospitalization. In the US, the Biden Administration COVID-19 action plan includes the Test to Treat initiative, where people can go to a pharmacy, take a COVID test, and immediately receive free Paxlovid if they test positive.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

Nicole M. Bouvier is an American physician who is Professor of Medicine at Icahn School of Medicine at Mount Sinai. Her research considers the environmental and viral factors that impact respiratory transmission of influenza viruses.

<span class="mw-page-title-main">Judith Aberg</span> American physician

Judith Aberg is an American physician who is the George Baehr Professor of Clinical Medicine at Mount Sinai Hospital. She was appointed Dean of System Operations for Clinical Sciences at the Icahn School of Medicine at Mount Sinai. Her research considered infectious diseases, including HIV/AIDS and COVID-19.

References

  1. ↑ "Liise-anne Pirofski, M.D. | Faculty Directory | Albert Einstein College of Medicine". www.einsteinmed.org.
  2. 1 2 3 4 5 Pirofski, Liise-anne (2017-11-10). "Virulence profile: Liise-anne Pirofski". Virulence. 9 (1): 275–277. doi:10.1080/21505594.2017.1382277. ISSN   2150-5594. PMC   5990341 . PMID   28956699.
  3. 1 2 3 4 5 6 7 Pirofski, Liise-anne (2017-09-15). "Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline". The Journal of Infectious Diseases. 216 (suppl_5): S611–S612. doi: 10.1093/infdis/jix270 . ISSN   0022-1899. PMID   28938039.
  4. 1 2 3 "Dr. Liise-anne Pirofski of Einstein College of Medicine Elected Fellow of American Academy of Microbiology – Yeshiva University News". 6 July 2007. Retrieved 2020-04-03.
  5. ↑ "AMWA". American Medical Women's Association. Retrieved 2020-04-03.
  6. ↑ "Three Infections You Should Worry About More Than Ebola". www.yahoo.com. Retrieved 2020-04-03.
  7. ↑ Extance, Andy (2010-03-01). "Biologics target bad bugs". Nature Reviews Drug Discovery. 9 (3): 177–178. doi:10.1038/nrd3129. ISSN   1474-1784. PMID   20190776. S2CID   12169762.
  8. ↑ Casadevall, Arturo; Pirofski, Liise-anne (2003). "The damage-response framework of microbial pathogenesis". Nature Reviews Microbiology. 1 (1): 17–24. doi:10.1038/nrmicro732. ISSN   1740-1534. PMC   7097162 . PMID   15040176.
  9. 1 2 "Dr. Liise-anne Pirofski Receives Lifetime Achievement Award | Einstein/Montefiore Department of Medicine | Albert Einstein College of Medicine". www.einstein.yu.edu. Retrieved 2020-04-03.
  10. 1 2 3 4 "Combating the COVID-19 Pandemic with Antibodies and a Patient Database". Albert Einstein College of Medicine. Retrieved 2020-04-03.
  11. ↑ "FDA Supports Effort To Develop COVID Treatment From Plasma Of Recovered Patients". NPR.org. Retrieved 2020-04-03.
  12. ↑ "How the blood of coronavirus survivors may protect others from COVID-19". Los Angeles Times. 2020-03-20. Retrieved 2020-04-03.
  13. ↑ Zhang, Sarah (2020-03-28). "America Needs Plasma From COVID-19 Survivors Now". The Atlantic. Retrieved 2020-04-03.
  14. ↑ "What Makes Me Sick Makes You Stronger: Convalescent Plasma as Treatment for COVID-19". ContagionLive. Retrieved 2020-04-03.
  15. ↑ "FDA to Allow for Plasma Therapy for COVID-19 Patients". The Scientist Magazine®. Retrieved 2020-04-03.
  16. ↑ Johnson, Elizabeth Weise and Mark. "Have you recovered from coronavirus? Want to help doctors find a treatment? Here's what they need from you". USA TODAY. Retrieved 2020-04-03.
  17. ↑ "Home | Division of Infectious Diseases | Albert Einstein College of Medicine". www.einstein.yu.edu.
  18. ↑ Pirofski, LA (15 September 2017). "Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline". The Journal of Infectious Diseases. 216 (suppl_5): S611–S612. doi: 10.1093/infdis/jix270 . PMID   28938039.
  19. ↑ "Harry Eagle Award for Outstanding Pre-Clerkship Teaching | Educational Resources | Albert Einstein College of Medicine". www.einstein.yu.edu. Retrieved 2020-04-03.
  20. ↑ "Dr. Pirofski to Deliver 2014 IDSA Maxwell Finland Lecture | Division of Infectious Diseases | Albert Einstein College of Medicine". www.einstein.yu.edu.
  21. ↑ "Pirofski Wins Einstein Faculty Mentoring Award | Einstein/Montefiore Department of Medicine | Albert Einstein College of Medicine". www.einstein.yu.edu. Retrieved 2020-04-03.
  22. ↑ "Maxwell Finland Lectureship". www.idsociety.org. Retrieved 2020-04-03.
  23. ↑ "Dr. Liise-anne Pirofski Receives ASM Research Training Award | Division of Infectious Diseases | Albert Einstein College of Medicine". www.einstein.yu.edu. Retrieved 2020-04-03.
  24. ↑ "2016 AAAS Fellows Honored for Advancing Science to Serve Society". American Association for the Advancement of Science. Retrieved 2020-04-03.
  25. ↑ Pirofski, Liise-Anne (3 October 2018). "What's Hot in ID Basic Science". Infectious Diseases Society of America.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.